BIA welcomes UK Human stem cell law

27 October 2008

The UK biotechnology sector's representative group has welcomed the decision by the House of Commons to pass the Human Fertilization and Embryology Bill, with minor amendments through the report stage and its third reading.

Aisling Burnand, the BioIndustry Association's chief executive, said: "the legislation was debated widely and at length throughout its passage through the House of Commons which has contributed to the development of a comprehensive piece of legislation." She added: "this Bill will help to enable the bioscience sector in the UK to continue to develop and grow. The research permitted by this Bill will be used to develop the techniques required for the production of stem cells, which could prove to be the source of treatments for diseases such as muscular dystrophy, Parkinson's and motor neurone disease."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight